InnovationsHIVTreatment
Meeting category
Date(s)
22 Nov 2022
Meeting type
Virtual Meeting
2
Organizer
Educational Partner
Sponsor logos
Erasmus Medical Center

Innovations in HIV Therapeutics - Europe/North America Edition 2022

Related Enduring Materials

Enduring Materials
Session 1: Novel Agents for HIV Treatment/Prevention & Innovations Beyond HIV -
15:10 CET
The Long-Acting Pipeline for HIV Treatment
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
15:25 CET
Long-Acting Pipeline for HIV Prevention
Laura Waters, MD, FRCP
Central & North West London NHS Foundation Trust, United Kingdom
15:40 CET
Implant & Device Innovations Beyond ART: Implication for HIV Prevention & Care
Marc Baum, BSc, PhD
Oak Crest Institute of Science, United States
15:55 CET
Panel Discussion
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Laura Waters, MD, FRCP
Central & North West London NHS Foundation Trust, United Kingdom
Marc Baum, BSc, PhD
Oak Crest Institute of Science, United States
Session 2: Practicalities of and Access to Long-Acting Technologies -
16:35 CET
Pharmacology of Injectable ART & Implications for Toxicity & Resistance
Marta Boffito, MD, PhD, FRCP
Chelsea and Westminster Hospital London, United Kingdom
16:50 CET
Implementation of Innovations and How to Expand Access
David H. Brown Ripin, PhD, BS
Clinton Health Access Initiative, United States
17:05 CET
Implementation of Long-Acting PrEP
Adam Spivak, MD
University of Utah, United States
17:20 CET
Panel Discussion
Marta Boffito, MD, PhD, FRCP
Chelsea and Westminster Hospital London, United Kingdom
David H. Brown Ripin, PhD, BS
Clinton Health Access Initiative, United States
Adam Spivak, MD
University of Utah, United States
Overview
Invitation to Join Innovations in HIV Therapeutics - Europe/North America Edition

Our faculty members invite you to join the Innovations in HIV Therapeutics - Europe/North America Edition on 22 November 2022!

The COVID-19 pandemic drastically changed the delivery of HIV care, but there is more on the horizon.

New compounds with diverse modes of action and novel formulations have the potential to revolutionize HIV service delivery even more, as these may allow longer dosing schedules, increase adherence and improve cost-efficacy.

Therefore, there is a continuous need for medical education on new (long-acting) antiretroviral therapies (ART), novel formulations, and devices to provide the best care.

In contrast to existing educational activities that focus on approved or late-stage clinical data on ART, this program offers a platform entirely dedicated to HIV preclinical and early clinical development. This platform will consider regional differences in health care systems, with a focus on Europe and North America region.

Welcome

The Innovations in HIV Therapeutics - Europe/North America Edition took place as a virtual meeting on 22 November 2022.

As the pipeline of HIV drugs continues to evolve and novel formulations and devices are on the horizon, the HIV Therapeutics forum provides a scientific program that keeps HIV-treating clinicians, pharmacologists, and virologists updated on the latest data present in preclinical and early clinical development.

New formulations, novel compounds, and their modes of action will be presented, as well as their pharmacological properties, potential drug-drug interactions, and possible toxicities.

This forum will be provided in a virtual half-day program accounting for the unique regional differences present in the Europe/North America region.

Program Director
Chair
General Information 
CME Accreditation
Innovations in HIV Therapeutics - Europe/North America Edition, Utrecht (Livestream), Netherlands, 22/11/2022-22/11/2022 has been granted 2 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama assn.org/education/earn-credit-participation-international-activities.
Who Should Attend?
- HIV-treating Clinicians
- Pharmacologists
- Virologists
- Researchers







Meeting Objectives
This meeting aims to:

- Update clinicians on the latest therapeutics and innovations in HIV (long-acting) therapeutics;
- Understand pharmacological properties, safety profile, and resistance of new long-acting ART;
- Evaluate how innovations in treatments can impact people living with HIV.
Learning Objectives
After participating in this activity, participants will be able to:

- Describe the innovations in HIV treatments, novel formulations and devices on the horizon;
- Define pharmacological properties, potential drug-drug interactions, possible toxicities, and resistance profiles of novel drugs;
- Reflect on the implementation of novel HIV (long-acting) therapeutics in various populations and settings.
Practical Information 
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the forum is English
Translation will not be provided.
Enduring Materials
Conference materials can be obtained upon registration at the registration desk at the Conference Venue.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this forum. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official forum sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Support
Acknowledgment
This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Endorsers

Innovations in HIV Therapeutics - Europe/North America Edition is endorsed by societies and organizations. Their support and collaboration are key to the success of this meeting!

If you would like your organization to endorse this forum, please contact Jeanne Kartika Tanujaya (Tika) at Tika.Tanujaya@amededu.com.

Educational Partner